Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women
- 1 July 2001
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 76 (1) , 38-43
- https://doi.org/10.1016/s0015-0282(01)01849-0
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal WomenJAMA, 1999
- Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 SitesScience, 1997
- Comparative Messenger Ribonucleic Acid Analysis of Immediate Early Genes and Sex Steroid Receptors in Human Leiomyoma and Healthy MyometriumJournal of Clinical Endocrinology & Metabolism, 1997
- Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and βEndocrinology, 1997
- Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulatorsMolecular Carcinogenesis, 1996
- A pharmacological review of raloxifeneJournal of Bone and Mineral Metabolism, 1996
- The effects of hormone replacement therapy on uterine fibroids in postmenopausal womenFertility and Sterility, 1996
- Does the Use of Postmenopausal Hormone Replacement Therapy Influence the Size of Uterine Leiomyomata? A Preliminary ReportMenopause, 1996
- Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.Journal of Clinical Investigation, 1994